文献速递妇科

超声引导经皮微波消融治疗单发大于300 cm³子宫肌瘤的有效性与安全性

Effectiveness and Safety of Ultrasound-guided Percutaneous Microwave Ablation for a Single Uterine Fibroid Greater than 300 cm3.
PubMed 文献 · J Minim Invasive Gynecol · 2022-12-20

本研究为回顾性观察性研究,纳入37例单发大于300 cm³子宫肌瘤患者,接受超声引导经皮微波消融治疗并随访12个月。所有患者均达到完全消融标准,病灶体积从术前334.28 cm³降至12个月时52.01 cm³(P<.001),体积缩小率84.00%,症状和生活质量评分显著改善,贫血患者血红蛋白显著升高。作者结论认为该治疗具有良好的临床疗效和高安全性。

要点

  • 37例单发大于300 cm³子宫肌瘤患者均达到完全消融标准,12个月病灶体积缩小率84.00%。
  • 术前与术后子宫肌瘤症状及健康相关生活质量问卷评分差异显著(P<.01),贫血患者血红蛋白显著升高(P<.001)。
  • 17例(45.95%)发生介入放射学会A至B级不良事件,无需临床干预或仅需简单临床干预。

核心结论

  • 超声引导经皮微波消融治疗单发大于300 cm³子宫肌瘤具有良好的临床疗效和高安全性。

研究设计与样本

  • 回顾性观察性研究,在中国吉林大学中日联谊医院开展,纳入37例经超声和空芯针活检诊断的单发大于300 cm³子宫肌瘤患者,均接受超声引导经皮微波消融,术后随访12个月。

主要发现

  • 37例患者均达到完全消融标准,病灶体积从术前334.28 cm³(95%CI 326.75-366.73)降至12个月随访时52.01 cm³(95%CI 46.95-74.69),差值280.15 cm³(95%CI 267.92-294.65,P<.001)。
  • 术后1、3、6、12个月病灶体积缩小率分别为27.30%(95%CI 24.12-31.45)、52.90%(95%CI 47.95-55.80)、67.90%(95%CI 63.03-70.77)和84.00%(95%CI 80.22-85.94)。
  • 术前与术后子宫肌瘤症状及健康相关生活质量问卷评分差异显著(P<.01),贫血患者术后血红蛋白水平显著升高(P<.001)。
  • 37例患者中29例(78.38%)疗效非常显著,8例(21.62%)疗效显著。
  • 17例(45.95%)发生介入放射学会A至B级不良事件,无需临床干预或仅需简单临床干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate the effectiveness and safety of ultrasound-guided percutaneous microwave ablation (MWA) for a single uterine fibroid greater than 300 cm3. DESIGN: Retrospective observational study. SETTING: China-Japan Union Hospital of Jilin University, China. PATIENTS: Thirty-seven patients each with a single fibroid greater than 300 cm3 diagnosed by ultrasound and core needle biopsy. INTERVENTIONS: Ultrasound-guided percutaneous MWA. MEASUREMENTS AND MAIN RESULTS: All patients were followed up for 12 months postoperatively to assess the postoperative lesion volume reduction rate, degree of symptomatic relief, improvements in quality of life, and occurrence of adverse events. All 37 patients met the criteria for complete ablation, and the lesion volume significantly decreased from 334.28 cm3 (95% confidence interval [CI] 326.75-366.73) preoperatively to 52.01 cm3 (95% CI, 46.95-74.69) at the 12-month follow-up (difference: 280.15 cm3; 95% CI, 267.92-294.65; p <.001). The lesion volume reduction rates at 1, 3, 6, and 12 months postoperatively were 27.30% (95% CI, 24.12-31.45), 52.90% (95% CI, 47.95-55.80), 67.90% (95% CI, 63.03-70.77), and 84.00% (95% CI, 80.22-85.94), respectively. The differences in the preoperative and postoperative Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire scores were significant (p <.01). The hemoglobin levels of the anemic patients were significantly elevated after the procedure (p <.001). Of the 37 patients in this study, 29 patients (78.38%) had a highly significant treatment effect, and 8 patients (21.62%) had a significant treatment effect. Seventeen patients (45.95%) had Society of Interventional Radiology grade A to B adverse effects that required no clinical intervention or only simple clinical intervention. CONCLUSION: Ultrasound-guided percutaneous MWA has good clinical efficacy and high safety in the treatment of a single uterine fibroid greater than 300 cm3.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Xia J, Teng D, Sui G, et al. Effectiveness and Safety of Ultrasound-guided Percutaneous Microwave Ablation for a Single Uterine Fibroid Greater than 300 cm3. J Minim Invasive Gynecol. 2022. PMID: 36563871. doi:10.1016/j.jmig.2022.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。